Clinical trial
Efficacy and Safety Evaluating Fispemifene in the Treatment of Hypogonadal Men…
NCT00415571 · QuatRx Pharmaceuticals Company, Industry · Completed
Key facts
| NCT number | NCT00415571 |
|---|---|
| Title | Efficacy and Safety Evaluating Fispemifene in the Treatment of Hypogonadal Men With Erectile Dysfunction Unresponsive to PDE5 Inhibitors |
| Official title | Efficacy and Safety of Fispemifene in the Treatment of Hypogonadal Men With Erectile Dysfunction Unresponsive to PDE5 Inhibitors: An 8-Week, Randomized, Double-Blind, Placebo-Controlled Study |
| Lead sponsor | QuatRx Pharmaceuticals Company, Industry |
| Collaborators | Hormos Medical Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Hypogonadism, Erectile Dysfunction |
| Intervention type | Drug |
| Interventions | Fispemifene (once daily for 8 weeks) |
| Enrollment | 72 |
| Start date | Dec 1, 2006 |
| Completion | Aug 1, 2008 |
| First posted | Dec 25, 2006 |
| Last update posted | Feb 3, 2010 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: